Literature DB >> 8040018

Trilateral retinoblastoma--incidence and outcome: a decade of experience.

L E Blach1, B McCormick, D H Abramson, R M Ellsworth.   

Abstract

PURPOSE: This report examines the incidence and outcome of trilateral retinoblastoma in children treated for retinoblastoma. A group of patients who are at highest risk for the development of trilateral retinoblastoma is defined. METHODS AND MATERIALS: Between 1979 and 1990, 117 children were treated with external beam radiation therapy for retinoblastoma, (97/117, bilateral). Median follow-up time was 68 months. The median age at diagnosis was 7 months.
RESULTS: Six cases of trilateral retinoblastoma were identified. The incidence of trilateral retinoblastoma in children with bilateral retinoblastoma was 6% (6/97) and 10% in those with a family history of retinoblastoma. The median age at diagnosis of RB in the children with trilateral retinoblastoma, was 3 months, younger than the median age of the entire retinoblastoma group. In all cases, the pineal region was excluded from the radiotherapy fields. Treatment for the trilateral retinoblastoma consisted of craniospinal axis radiation therapy and chemotherapy in three patients, chemotherapy alone in two, and no treatment in one. All patients died from this disease. Overall, of the 117 children treated at our institution for retinoblastoma with a median follow-up of 68 months, 12 have died. Trilateral retinoblastoma was the major cause of death, accounting for 50% (6/12) of deaths.
CONCLUSION: Trilateral retinoblastoma is a major and under-appreciated cause of mortality in the first 5 years after the diagnosis of bilateral retinoblastoma. A more aggressive approach toward screening a defined population of childhood retinoblastoma survivors may be warranted.

Entities:  

Mesh:

Year:  1994        PMID: 8040018     DOI: 10.1016/0360-3016(94)90560-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

Review 1.  Chemotherapy for retinoblastoma: a current topic.

Authors:  P T Finger; G Czechonska; H Demirci; A Rausen
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Germ-line and somatic DICER1 mutations in pineoblastoma.

Authors:  Leanne de Kock; Nelly Sabbaghian; Harriet Druker; Evan Weber; Nancy Hamel; Suzanne Miller; Catherine S Choong; Nicholas G Gottardo; Ursula R Kees; Surya P Rednam; Liselotte P van Hest; Marjolijn C Jongmans; Shalini Jhangiani; James R Lupski; Margaret Zacharin; Dorothée Bouron-Dal Soglio; Annie Huang; John R Priest; Arie Perry; Sabine Mueller; Steffen Albrecht; David Malkin; Richard G Grundy; William D Foulkes
Journal:  Acta Neuropathol       Date:  2014-07-15       Impact factor: 17.088

3.  Trilateral retinoblastoma: A systematic review of 211 cases.

Authors:  Ryuya Yamanaka; Azusa Hayano; Yasuo Takashima
Journal:  Neurosurg Rev       Date:  2017-08-16       Impact factor: 3.042

4.  Genes and environment: effects on the development of second malignancies in retinoblastoma survivors.

Authors:  Amy C Schefler; Ruth A Kleinerman; David H Abramson
Journal:  Expert Rev Ophthalmol       Date:  2008-02-01

5.  Successful treatment of early detected trilateral retinoblastoma using standard infant brain tumor therapy.

Authors:  Karen D Wright; Ibrahim Qaddoumi; Zoltan Patay; Amar Gajjar; Matthew W Wilson; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2010-09       Impact factor: 3.167

Review 6.  US and MRI of pediatric ocular masses with histopathological correlation.

Authors:  Rachel C Brennan; Matthew W Wilson; Sue Kaste; Kathleen J Helton; M Beth McCarville
Journal:  Pediatr Radiol       Date:  2012-03-31

Review 7.  Molecular genetics of pineal region neoplasms.

Authors:  M D Taylor; T G Mainprize; J A Squire; J T Rutka
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

8.  A Potential Role For Apparent Diffusion Coefficient in the Diagnosis of Trilateral Retinoblastoma.

Authors:  Sameer Farouk Sait; Sofia Haque; Sasan Karimi; Karim J Rebeiz; Jasmine H Francis; Brian P Marr; David H Abramson; Mark M Souweidane; Ira J Dunkel
Journal:  J Pediatr Hematol Oncol       Date:  2020-04       Impact factor: 1.289

9.  p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor.

Authors:  Raya Saab; Carlos Rodriguez-Galindo; Kelly Matmati; Jerold E Rehg; Shannon H Baumer; Joseph D Khoury; Catherine Billups; Geoffrey Neale; Kathleen J Helton; Stephen X Skapek
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

10.  Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study.

Authors:  Bryan K Li; Alexandre Vasiljevic; Christelle Dufour; Fupan Yao; Ben L B Ho; Mei Lu; Eugene I Hwang; Sridharan Gururangan; Jordan R Hansford; Maryam Fouladi; Sumihito Nobusawa; Annie Laquerriere; Marie-Bernadette Delisle; Jason Fangusaro; Fabien Forest; Helen Toledano; Palma Solano-Paez; Sarah Leary; Diane Birks; Lindsey M Hoffman; Alexandru Szathmari; Cécile Faure-Conter; Xing Fan; Daniel Catchpoole; Li Zhou; Kris Ann P Schultz; Koichi Ichimura; Guillaume Gauchotte; Nada Jabado; Chris Jones; Delphine Loussouarn; Karima Mokhtari; Audrey Rousseau; David S Ziegler; Shinya Tanaka; Scott L Pomeroy; Amar Gajjar; Vijay Ramaswamy; Cynthia Hawkins; Richard G Grundy; D Ashley Hill; Eric Bouffet; Annie Huang; Anne Jouvet
Journal:  Acta Neuropathol       Date:  2019-12-09       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.